Five more health apps have obtained reimbursement in Germany since August 2025

In Germany, digital health applications (DiGAs) that can be prescribed by physicians and psychotherapists and reimbursed by statutory health insurers are listed in the Directory of Digital Health Applications maintained by the Federal Institute for Drugs and Medical Devices (BfArM). As of February 23, 2026, a total of 61 apps are available in the Directory and thus eligible for reimbursement.

Between late August 2025 and late February 2026, five new health apps in nephrology and urology, neurology and neurosurgery, obstetrics and gynecology, and the orthopedics field were added to the Directory. Some examples are provided below.

On October 27, 2025, the “Kranus Mictera” health app was introduced in the Directory. “Kranus Mictera”, developed by Kranus Health GmbH, Germany, is a digital health application designed for the treatment of urinary incontinence in women. The app offers a simple, personalized, and scientifically validated therapy based on multimodal approaches. It aims to help women with stress, urge, and mixed incontinence alleviate symptoms, improve quality of life, and take an active role in their treatment. The primary goal is to reduce the number of incontinence episodes and decrease bothersome urinary urgency. Kranus Mictera is intended to be used as a supplement to standard medical treatment. It is available in German at a tariff of €681.30.

“Vera-App für Wechseljahresbeschwerden” by Endo Health GmbH, Germany, introduced in the Directory on January 20, 2026, supports patients experiencing menopausal symptoms with evidence-based, guideline-compliant content, methods, and exercises as part of a multimodal approach to the treatment of menopausal complaints. The Vera app is intended for individuals suffering from at least moderate menopausal symptoms who have been diagnosed with conditions associated with menopause and the climacteric. An additional requirement is that the patient is not receiving hormone therapy. “Vera-App für Wechseljahresbeschwerden” is available in German at a tariff of €598.95.

On February 4, 2026, the “Axia - für axiale Spondyloarthritis (axSpA)” health app was introduced in the DiGA Directory. “Axia - für axiale Spondyloarthritis (axSpA)”, developed by Applimeda GmbH, Germany, is a digital health app designed for patients with axial spondyloarthritis (axSpA). The app uses a gamified approach to guide patients through guideline-based, axSpA-specific exercise therapy and motivates them to stay engaged over the long term. In addition, it supports disease management through educational content, reminders, and documentation features. The app serves as a therapy companion across all stages of the disease, addressing and supporting key non-pharmacological treatment measures for axial spondyloarthritis (tertiary prevention). “Axia - für axiale Spondyloarthritis (axSpA)” is available in German at a tariff of €599.

The full details in German can be found here (Kranus Mictera), here (Vera-App für Wechseljahresbeschwerden), and here (Axia - für axiale Spondyloarthritis)

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.